Edition:
United Kingdom

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

1,329JPY
20 Jul 2018
Change (% chg)

¥-20 (-1.48%)
Prev Close
¥1,349
Open
¥1,336
Day's High
¥1,369
Day's Low
¥1,308
Volume
1,310,200
Avg. Vol
1,309,581
52-wk High
¥3,195
52-wk Low
¥1,304

Latest Key Developments (Source: Significant Developments)

Sosei Group says change of corporate auditor
Wednesday, 16 May 2018 

May 16 (Reuters) - Sosei Group Corp <4565.T>:Says it appoints Ernst & Young ShinNihon LLC as new corporate auditor, to replace Deloitte Touche Tohmatsu LLC , effective June 22 .  Full Article

Sosei Says Does Not Intend To Make An Offer For Vectura
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Sosei Group Corp::STATEMENT RE PRESS COMMENT.CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA.SOSEI WILL, EXCEPT WITH CONSENT OF UK PANEL ON TAKEOVERS AND MERGERS, BE BOUND BY RESTRICTIONS CONTAINED IN RULE 2.8 OF CODE.  Full Article

Sosei Group says new share prices
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Sosei Group Corp <4565.T>:Says it will issue new shares of its common stock via overseas offering, with the issue price of 10,800 yen per share (22.36 billion yen in total) and paid-in price of 10,283.55 yen per share (21.29 billion yen in total).Says payment date on Nov. 27.Previous news was disclosed on Nov. 10.  Full Article

Sosei Group to issue 2.1 mln new shares
Friday, 10 Nov 2017 

Nov 10(Reuters) - Sosei Group Corp <4565.T>:Says it plans to issue 2.1 million new shares through overseas offering .Proceeds to be mainly used for drug discovery and research and development related fund .  Full Article

Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)
Thursday, 9 Nov 2017 

Nov 9(Reuters) - Sosei Group Corp <4565.T>:Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB).Says it will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018 .  Full Article

Mina Therapeutics partners with Boehringer Ingelheim
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Sosei Group Corp <4565.T>:Strategic minority investment company Mina Therapeutics enters into collaboration and licensing agreement with Boehringer Ingelheim.Under agreement, Mina to receive an upfront payment, funding and payments of up to EUR 307 million​.Mina is also entitled to double-digit royalties on sales of selected products resulting from partnership​.No further financial details were disclosed​.  Full Article

Sosei Group says completion of Japanese Phase III clinical study of SO-1105 for oropharyngeal candidiasis
Monday, 29 Aug 2016 

Sosei Group <4565.T>: Says its Japanese subsidiary Sosei Co. Ltd. has completed the Japanese Phase III study of SO-1105 (miconazole 50 mg, muco-adhesive tablet) for the treatment of oropharyngeal candidiasis; meeting the primary endpoint as requested for submission . Says the study was an open-label, randomized, multi-site, parallel-group, comparative clinical study to investigate the efficacy and safety of SO-1105 in comparison with a commercialized formulation of miconazole in patients with oropharyngeal candidiasis in Japan .Says the cure rate after the completion of the targeted study medication period with SO-1105 was the same as the comparator in terms of the primary endpoint.  Full Article